[Treatment of anxiety in Parkinson's disease with bromazepam]

The Authors observe that anxiety is a rather frequent symptom in parkinsonian patients. The possible mechanisms are reviewed. In a double blind cross-over trial, a new antianxiety agent (Lexotan, Roche) was compared with Placebo, to delineate the therapeutic effect in anxious parkinsonian patients. A noteworthy activity was shown by the active drug, while after Placebo a deterioration of anxiety was demonstrated. Tremor was also alleviated by Lexotan and the importance of emotional troubles on tremor seems to be confirmed.